Aryl substituted thiazolidinones and the use thereof

Details Aryl substituted thiazolidinones and the use thereof Aryl substituted thiazolidinones and the use thereof

2007-01-30

2007-01-30

Powers, Fiona T. (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C514S326000, C514S342000, C514S369000, C544S133000, C546S209000, C546S269700, C548S186000

Reexamination Certificate

active

10195530

ABSTRACT:
This invention relates aryl substituted thiazolidinones of Formula I:or a pharmaceutically acceptable salt, or solvate thereof, wherein R1and R2, are defined in the specification. The invention is also directed to the use of compounds of Formula I for the treatment of neuronal damage following global and focal ischemia, for the treatment or prevention of neurodegenerative conditions such as amyotrophic lateral sclerosis (ALS), and for the treatment, prevention or amelioration of both acute or chronic pain, as antitinnitus agents, as anticonvulsants, and as antimanic depressants, as local anesthetics, as antiarrhythmics and for the treatment or prevention of diabetic neuropathy.

REFERENCES:
patent: 3309377 (1967-03-01), Surrey
patent: 3377355 (1968-04-01), Surrrey
patent: 4933453 (1990-06-01), Hrib et al.
patent: 5061720 (1991-10-01), Walsh et al.
patent: 5229388 (1993-07-01), Hrib et al.
patent: 6335354 (2002-01-01), Hogenkamp
patent: 6414011 (2002-07-01), Hogenkamp et al.
patent: 2002/0006947 (2002-01-01), Hogenkamp et al.
patent: 2002/0040025 (2002-04-01), Hogenkamp et al.
patent: 2003/0055088 (2003-03-01), Shao et al.
patent: 22 59 222 (1973-06-01), None
patent: 0 292 305 (1988-11-01), None
patent: 0 524 595 (1993-01-01), None
patent: 0 699 675 (1996-03-01), None
patent: 0 705 816 (1996-04-01), None
patent: 1 409 898 (1975-10-01), None
patent: WO 99/62891 (1999-12-01), None
patent: WO 00/57877 (2000-10-01), None
patent: WO 00/63197 (2000-10-01), None
Andres Bloorganic an Medicinal Chemistry Letters 10 (2000) 715-7.
Bensimon, G., et al., “A Controlled Trial of Riluzole in Amyotrophic Lateral Sclerosis,”New Engl. J. Med. 330:585-591, Massachusetts Medical Society (1994).
Brown, C.M., et al., “Neuroprotective properties of lifarizine compared with those of other agents in a mouse model of focal cerebral ischaemia,”British J. Pharmacol. 115:1425-1432, Stockton Press (1995).
Buchan, A.M., et al., “AMPA Antagonists: Do They Hold More Promise for Clinical Stroke Trials Than NMDA Antagonists?”Stroke Suppl. I 24:I-148-I-152, American Heart Association (1993).
Catterall, W.A., “Neurotoxins that Act on Voltage-Sensitive Sodium Channels in Excitable Membranes,”Ann. Rev. Pharmacol. Toxicol. 20:15-43, Annual Reviews, Inc. (1980).
Catterall, W.A., “Common modes of drug action on Na+channels: local anesthetics, antiarrhythmics and anticonvulsants,”Trends Pharmacol. Sci. 8:57-65, Elsevier Science B.V. (1987).
Catterall, W.A., “Structure and Function of Voltage-Sensitive Ion Channels,”Science 242:50-61, American Association for the Advancement of Science (1988).
Creveling, C.R., et al., “Batrachotoxin-Induced Depolarization and [3H] Batrachotoxinin-A 20α-Benzoate Binding in a Vesicular Preparation from Guinea Pig Cerebral Cortex,”Mol. Pharmacol. 23:350-358, The American Society for Pharmacology and Experimental Therapeutics (1983).
Denicoff, K.D., et al., “Efficacy of Carbamazepine Compared With Other Agents: A Clinical Practice Survey,”J. Clin. Psychiatry 55:70-76, Physicians Postgraduate Press (1994).
Donaldson, I., “Tegretol: A double blind trial in tinnitus,”J. Laryngol. Otol. 95:947-951, Headley Brothers (1981).
Graham, S.H., et al., “Neuroprotective Effects of a Use-Dependent Blocker of Voltage-Dependent Sodium Channels, BW619C89, in Rat Middle Cerebral Artery Occlusion,”J. Pharmacol. Exp. Ther. 269:854-859, Williams & Wilkins (1994).
Graham, S.H., et al., “A Dose-Response Study of Neuroprotection Using the AMPA Antagonist NBQX in Rat Focal Cerebral Ischemia,”J. Pharmacol. Exp. Ther. 276:1-4, Williams & Wilkins (1996).
Hunskaar, S., et al., “Formalin test in mice, a useful technique for evaluating mild analgesics,”J. Neurosci. Methods 14:69-76, Elsevier Science B.V. (1985).
Iwasaki, Y., et al., “CNQX prevents spinal motor neuron death following sciatic nerve transection in newborn rats,”J. Neurological Sci. 134:21-25, Elsevier Science B.V. (1995).
Leff, P., and Dougall, I.G., “Further concerns over Cheng-Prusoff analysis,”Trends Pharmacol. Sci. 14:110-112, Elsevier Science Publishers Ltd. (1993).
Majumdar, B., et al., “An electrocochleographic study of the effects of lignocaine on patients with tinnitus,”Clin. Otolaryngol. 8:175-180, Blackwell Scientific Publications (1983).
Møller, A.R., “Similarities Between Chronic Pain and Tinnitus,”Am. J. Otol. 18:577-585, Lippincott-Raven (1997).
Ohizumi, Y., et al., “Specific Inhibition of [3H] Saxitoxin Binding to Skeletal Muscle Sodium Channels by Geographutoxin II, a Polypeptide Channel Blocker,”J. Biol. Chem. 261:6149-6152, The American Society of Biological Chemists, Inc. (1986).
Sheardown, M.J., et al., “AMPA, but not NMDA, receptor antagonism is neuroprotective in gerbil global ischaemia, even when delayed 24 h,”Eur. J. Pharmacol. 236:347-353, Elsevier Science B.V. (1993).
Simpson, J.J., and Davies, W.E., “Recent advances in the pharmacological treatment of tinnitus,”Trends Pharmacol. Sci. 20:12-18, Elsevier Science London (1999).
Stys, P.K., et al., “Ionic Mechanisms of Anoxic Injury in Mammalian CNS White Matter: Role of Na+Channels and Na+—Ca2+Exchanger,”J. Neurosci. 12:430-439, Society for Neuroscience (1992).
Taylor, C.P., and Meldrum, B.S., “Na+channels as targets for neuroprotective drugs,”Trends Pharmacol. Sci. 16:309-316, Elsevier Science Ltd. (1995).
Tonndorf, J., “The analogy between tinnitus and pain: A suggestion for a physiological basis of chronic tinnitus,”Hear. Res. 28:271-275, Elsevier Science B.V. (1987).
Woodward, R.M., et al., “Effects of Steroids on γ-Aminobutyric Acid Receptors Expressed inXenopusOocytes by Poly(A)+RNA from Mammalian Brain and Retina,”Mol. Pharmacol. 41:89-103, Williams and Wilkins (1992).
Wrathall, J.R., et al., “Amelioration of Functional Deficits from Spinal Cord Trauma with Systemically Administered NBQX, an Antagonist of Non-N-methyl-D-aspartate receptors,”Exp. Neurol. 137:119-126, Academic Press, Inc. (1996).
Koga, T., et al., “The protective effects of CP-060S on ischaemia- and reperfusion-induced arrhythmias in anaesthetized rats,”Br. J. Pharmacol. 123:1409-1417, Stockton Press (1998).
International Search Report for International Patent Application No. PCT/US02/22367, mailed Oct. 9, 2002.
Andres, C.J., et al., “4-Thiazolidinones: Novel Inhibitors of the Bacterial Enzyme MurB,”Bioorg. Med. Chem. Lett. 10:715-717, Pergamon Press (2000).
Bartoszyk, G.D., et al., “Ralitoline: a thiazolidinone,”Curr. Probl. Epilepsy 4:309-311, John Libbey (1986).
Bhat, A.R., et al., “Synthesis and Biological Activity of Some 3-(1,3,4-oxadiazol-2-yl)-2-aryl-4-thiazolidinones,”Indian Drugs 21:129-134, Indian Drug Manufacturers' Association (1984).
Capan, G., et al., “Synthesis and Anticonvulsant Activity of New 3-[(2-furyl)carbonyl]amino-4-thiazolidinone and 2-[(2-furyl)carbonyl]hydrazono-4-thiazoline Derivatives,”Il Farmaco 51:729-732, Societa Chimica Italiana (1996).
Cesur, N., et al., “New Acylthiosemicarbazides, Thiazolidinones, and 1,3,4-Oxadiazoles as Possible Anticonvulsants,”Arch. Pharm. (Weinheim, Ger.) 325:623-624, VCH Verlagsgesellschaft mbH (1992).
El-Meligie, S., “Synthesis of Certain Thiazolidinone Derivatives as Possible Anticonvulsants,”Bull. Fac. Pharm. Cairo Univ. 28:35-37, Cairo University (1990).
El-Shafei, A.K., and Hassan, K.M., “Synthesis of Some New N-Oxidopyridylthiazolidin-4-ones,”Curr. Sci. 52:633-635, Current Science Association (1983).
Ergenc, N., and Capan, G., “Synthesis and Anticonvulsant Activity of New 4-Thiazolidone and 4-Thiazoline Derivatives,”Il Farmaco 49:449-451, Societa Chimica Italiana (1994).
Fischer, W., et al., “Anticonvulsant and sodium channel blocking effects of ralitoline

Affiliated with

Also associated with

Rating

Aryl substituted thiazolidinones and the use thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Aryl substituted thiazolidinones and the use thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Aryl substituted thiazolidinones and the use thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3759229